Recommended Topic Related To:

Rixubis

"The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to require less fre"...

Rixubis

Rixubis Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Rixubis [Coagulation Factor IX (Recombinant)] is an antihemophilic factor used to control and prevent bleeding episodes in adults with hemophilia B, for perioperative management in adults with hemophilia B, and for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia B. It is not indicated for induction of immune tolerance in patients with hemophilia B. Common side effects include changes in the sense of taste, pain in extremities, and positive furin antibody test.

The initial dose of Rixubis is based on body weight. Rixubis may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Rixubis should be administered only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our Rixubis [Coagulation Factor IX (Recombinant)] Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Rixubis FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The most common adverse reactions observed in > 1% of subjects in clinical studies were dysgeusia, pain in extremity, and positive furin antibody test.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

During clinical development, in a combined study, 91 male previously treated patients (PTPs; exposed to a factor IX-containing product for ≥ 150 days) received at least one infusion of RIXUBIS as part of either on-demand treatment of bleeding episodes, perioperative management of major and minor surgical, dental, or other invasive procedures, routine prophylaxis, or pharmacokinetic evaluation of RIXUBIS. Six subjects (6.6%) were < 6 years of age, 10 (11%) were 6 to < 12 years of age, 3 (3.3%) were adolescents (12 to < 16 years of age), and 72 (79%) were adults (16 years of age and older). The subjects received a total of 7,353 infusions with a median of 85 infusions of RIXUBIS (range 3 to 212 infusions), for a median of 83 exposure days (range 83 to 209 days).

A total of 161 adverse events were reported in 48 (52.7%) of the 91 subjects. Adverse reactions that occurred in > 1% of subjects are shown in Table 3.

Table 3 : Summary of Adverse Reactions

System Organ Class Adverse Reactions (AR) Number of ARs
(N)
Number of Subjects
(N=91)
n (%)
Percent per Infusion
(N=7353)
Nervous System Disorders Dysgeusia 2 1 (1.1%) 0.03%
Musculoskeletal and Connective Tissue Disorders Pain in extremity 1 1 (1.1%) 0.01%
Investigations Positive furin antibody testa 1 1 (1.1%) 0.01%
Factor IX or furin antibodies of indeterminate specificitya 9 7 (7.7%) 0.12%
a See Immunogenicity.

Immunogenicity

All 91 subjects were monitored for inhibitory and binding antibodies to factor IX, and binding antibodies to CHO protein and furin, at the following time points: at screening, at 72 hours following the first infusion of RIXUBIS and the commercial recombinant factor IX product in the cross-over portion of the pharmacokinetic study, after 5 and 13 weeks following first exposure to RIXUBIS, and thereafter every 3 months. Antibodies against furin were tested by an in-house enzyme-linked immunosorbent assay (ELISA). A titer of 1:20 or 1:40 was considered to be indeterminate for the above validated assay, as these titers were too low to be verified by the confirmatory assay.

No subjects developed neutralizing antibodies to factor IX. Thirteen subjects (14.3%) developed low-titer, non-neutralizing antibodies against factor IX at one or more time points. Two of these 13 subjects were found to have these antibodies at screening, prior to receiving RIXUBIS. No clinical adverse findings were observed in any of these 13 subjects.

Thirteen subjects (14.3%) had signals for antibodies against furin (indeterminate specificity). Four of these 13 subjects expressed signals for antibodies at screening, prior to RIXUBIS treatment. An additional subject had an antibody signal after treatment with the comparator product and prior to RIXUBIS treatment. Another additional subject had a positive titer of 1:80 that was not present when checked at a later time point and therefore considered transient. A second subject had a positive antibody signal after the data cutoff date that was also transient. No clinical adverse findings were observed in any of these 15 subjects.

In a study of 500 normal volunteers, using the same assay as in the clinical trial, 7% had titers of 1:20 or 1:40 and 1.2% had higher titers ranging from 1:80 to 1:320. These antibodies are thought to be part of a natural immune system response. To date, these antibodies have not been associated with any clinical adverse findings.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.

Thrombogenicity

There was no clinical evidence of thromboembolic complications in any of the subjects. Out-of-range values for thrombogenicity markers (thrombin-antithrombin III, prothrombin fragment 1.2, and D-dimer), determined during the pharmacokinetic portion of the combined study, did not reveal any pattern indicative of clinically relevant thrombogenicity with either RIXUBIS or a comparator factor IX-containing product.

Post-marketing Experience

Because the following reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Hypersensitivity (including symptoms such as dyspnea, pruritus)

The following class adverse reactions have been seen with another recombinant factor IX: inadequate factor IX recovery, inhibitor development, anaphylaxis, angioedema, hypotension, and thrombosis.

Read the entire FDA prescribing information for Rixubis (Coagulation Factor IX (Recombinant) for Intramuscular Injection) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD